Clinical Trials & Research Studies in United Kingdom(Updated 8/25)

Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

NCT05612035

Recruiting

Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take frespaciguat can walk farther in 6 minutes at Week 24 compared to people who take placebo.

Gender:

ALL

Ages:

Between 40 years and 85 years

Trial Updated:

07/24/2025

Locations: UCSF Helen Diller Medical Center at Parnassus Heights ( Site 0110), San Francisco, California +83 locations

UCSF Helen Diller Medical Center at Parnassus Heights ( Site 0110), San Francisco, California

University of Colorado Anschutz Medical Campus-University of Colorado Hospital Cardiac and Vascular ( Site 0101), Aurora, Colorado

Clinovation Intl. Corp. ( Site 0108), Sebring, Florida

Alexian Brothers Medical Center-Pulmonary ( Site 0109), Elk Grove Village, Illinois

University of Iowa ( Site 0103), Iowa City, Iowa

University of Kansas Medical Center-IM-Pulmonary and Critical Care Medicine ( Site 0102), Kansas City, Kansas

Lexington VA Medical Center - Cooper Division ( Site 0137), Lexington, Kentucky

Corewell Health ( Site 0133), Grand Rapids, Michigan

Mayo Clinic in Rochester, Minnesota ( Site 0131), Rochester, Minnesota

Creighton University Clinical Research Office ( Site 0123), Omaha, Nebraska

University of New Mexico Hospital ( Site 0146), Albuquerque, New Mexico

UNC Health - Eastowne Medical Office-Clinical Trials Unit ( Site 0147), Chapel Hill, North Carolina

Temple University Hospital ( Site 0104), Philadelphia, Pennsylvania

UPMC Montefiore University Hospital-Department of Medicine ( Site 0149), Pittsburgh, Pennsylvania

UT Southwestern Medical Center ( Site 0114), Dallas, Texas

The University of Texas Health Science Center at Houston ( Site 0105), Houston, Texas

Intermountain Medical Center-Division of Pulmonary & Critical Care Medicine ( Site 0140), Murray, Utah

University of Virginia Health System-Division of Pulmonary and Critical Care Medicine ( Site 0111), Charlottesville, Virginia

Fundación Respirar ( Site 0305), Caba, Buenos Aires

Centro Medico Capital ( Site 0301), La PLata, Buenos Aires

Instituto de Cardiologia de Tucuman-Area de Investigacion Clinica ( Site 0303), San Miguel de Tucumán, Tucuman

Hospital Britanico de Buenos Aires ( Site 0307), Caba, Not set

Hospital Privado Universitario de Córdoba-Clinical Cardiology Department ( Site 0302), Cordoba, Not set

Royal Prince Alfred Hospital-Department of Respiratory Medicine ( Site 0903), Camperdown, New South Wales

Westmead Hospital ( Site 0902), Westmead, New South Wales

WESLEY RESEARCH INSTITUTE Limited ( Site 0906), Auchenflower, Queensland

The Prince Charles Hospital ( Site 0904), Brisbane, Queensland

Mater Misericordiae Limited ( Site 0905), South Brisbane, Queensland

Medizinische Universität Graz-Klinische Abteilung für Pulmonologie ( Site 1201), Graz, Steiermark

Medizinische Universitaet Innsbruck ( Site 1202), Innsbruck, Tirol

Université Libre de Bruxelles - Hôpital Erasme ( Site 1302), Brussels, Bruxelles-Capitale, Region De

UZ Leuven ( Site 1301), Leuven, Vlaams-Brabant

Clinica Cardio VID ( Site 0504), Medellín, Antioquia

Ciensalud Ips S A S ( Site 0508), Barranquilla, Atlantico

Fundación Valle del Lili ( Site 0509), Cali, Valle Del Cauca

Centro de Investigaciones Clinicas SAS ( Site 0505), Cali, Valle Del Cauca

C.H.U Hôpital Nord ( Site 1503), Marseille, Bouches-du-Rhone

Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois ( Site 1502), Vandoeuvre lès Nancy, Lorraine

CHU Angers ( Site 1506), Angers, Maine-et-Loire

Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre-Pneumologie ( Site 1501), Le Kremlin-Bicêtre, Paris

Centre Hospitalier Universitaire de Poitiers ( Site 1505), Poitiers, Vienne

Thoraxklinik-Heidelberg gGmbH-Zentrum für Pulmonale Hypertonie ( Site 1603), Heidelberg, Baden-Wurttemberg

UKGM Gießen/Marburg ( Site 1604), Gießen, Hessen

Medizinische Hochschule Hannover ( Site 1602), Hannover, Niedersachsen

Universitaetsklinikum Carl Gustav Carus Dresden ( Site 1601), Dresden, Sachsen

Universitätsklinikum Schleswig-Holstein-Pneumologie ( Site 1605), Luebeck, Schleswig-Holstein

Unidad De Diagnostico Cardiologico-Unidad de Diagnostico Cardiologico ( Site 0605), Guatemala City, Not set

Private Practice - Dr. Jeremias Guerra Mejia ( Site 0603), Guatemala City, Not set

MEDI-K ( Site 0607), Guatemala, Not set

Clinica Medica ( Site 0601), Guatemala, Not set

Rambam Health Care Campus ( Site 1701), Haifa, Not set

Rabin Medical Center ( Site 1702), Petah Tikva, Not set

Cattinara Hospital ( Site 1801), Trieste, Friuli-Venezia Giulia

Ospedale San Gerardo-ASST Monza-Cardio Vasolare- Clinica pneumologica ( Site 1802), Monza, Lombardia

ISMETT Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione ( Site 1804), Palermo, Not set

Gachon University Gil Medical Center ( Site 1101), Namdong-gu, Incheon

Seoul National University Hospital ( Site 1103), Seoul, Not set

Asan Medical Center ( Site 1102), Seoul, Not set

Samsung Medical Center ( Site 1104), Seoul, Not set

Centro Médico Nacional Siglo XXI ( Site 0708), Mexico City, Distrito Federal

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran ( Site 0704), Mexico City, Distrito Federal

INVECORDIS S.C. ( Site 0703), Hacienda De Las Palmas, Not set

Instituto Nacional de Cardiologia Ignacio Chavez ( Site 0701), Mexico, Not set

Unidad de Investigacon de la Clinica Internacional ( Site 0804), Cercado De Lima, Lima

Clinica Ricardo Palma-Centro de Investigacion de Enfermedades Respiratorias Thorax ( Site 0806), San Isidro, Lima

Clínica Providencia ( Site 0803), San Miguel, Lima

Charlotte Maxeke Johannesburg Academic Hospital ( Site 2108), Johannesburg, Gauteng

Netcare Milpark Hospital ( Site 2103), Johannesburg, Gauteng

Netcare St Augustine's Hospital ( Site 2105), Durban, Kwazulu-Natal

TREAD Research ( Site 2101), Cape Town, Western Cape

Hospital Universitario Marqués de Valdecilla-Pneumology ( Site 2003), Santander, Cantabria

HOSPITAL CLÍNIC DE BARCELONA ( Site 2001), Barcelona, Cataluna

Parc de Salut Mar - Hospital del Mar ( Site 2006), Barcelona, Not set

Hospital Universitari Vall d'Hebron ( Site 2002), Barcelona, Not set

HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 2005), Sevilla, Not set

University Hospital Basel ( Site 2205), Basel, Basel-Stadt

UniversitätsSpital Zürich ( Site 2201), Zürich, Zurich

Cantonal Hospital St.Gallen ( Site 2203), Sankt Gallen, Not set

Hacettepe Universite Hastaneleri ( Site 2301), Ankara, Not set

Ankara Bilkent Şehir Hastanesi. ( Site 2307), Ankara, Not set

Eskisehir Osmangazi University-Cardiology ( Site 2304), Eskisehir, Not set

Istanbul Universitesi Istanbul Tıp Fakultesi Hastanesi-Chest Disease ( Site 2302), Istanbul, Not set

Hammersmith Hospital-Department of Cardiology ( Site 2401), London, London, City Of

Sheffield Teaching Hospitals NHS Foundation Trust-Clinical Research Facility ( Site 2405), Sheffield, Not set

Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease

Register for Updates

Learn More ›

fertiShare Evaluation

NCT06587360

Recruiting

Sharing bad news (SBN) is a daily challenge for fertility staff and patients. Bad news happens at all stages of fertility care and includes e.g., diagnosing infertility, reporting unexpected, repeated, or definitive treatment failure. Extensive evidence shows that SBN triggers stress in staff due to anticipation of negative emotions and evaluations or, in extreme cases, even complaints and lawsuits. Inability to manage bad news can increase negative emotions in patients and fuel distrust, potent... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/24/2025

Locations: The Newcastle Upon Tyne Hospitals Nhs Foundation Trust, Newcastle, Newcastle upon Tyne +4 locations

Conditions: Infertility Assisted Reproductive Technology

Register for Updates

Learn More ›

AVEIR™ Leadless Pacemaker (LP) United Kingdom (UK) Registry

NCT06854484

Recruiting

This observational study will follow patients requiring implantation of leadless pacemaker for 5 years after implantation. The main goal is to evaluate the long term safety and efficacy of AVEIR™ leadless pacemaker device in the usual clinical settings within the UK National Health Service. In addition, the study will collect data to understand patient characteristics receiving this type of pacemaker.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/24/2025

Locations: Royal Brompton Hospital, London, UK +1 locations

Conditions: Bradycardia, Atrio-Ventricular Block, Syncope

Register for Updates

Learn More ›

Respiratory Parameters Using Advanced Airways During In-hospital Cardiac Arrest

NCT06580652

Recruiting

The investigators aim to investigate the real life volumes of air delivered to the lungs when rescuers deliver these breaths by hand as part of resuscitation attempts during cardiac arrest. The study will compare the volumes achieved using different devices which are routinely used to provided an airway during routine cardiac arrest care. Volumes will be measured using a small non intrusive device which sits in the airway circuit and measures flow of air in real time. The patients chosen for thi... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/23/2025

Locations: Royal United Hospital Bath, Bath, Banes

Conditions: Cardiac Arrest

Register for Updates

Learn More ›

Barts Sex-CAD Database - Sex Hormones and Inflammatory Status in Coronary Artery Disease

NCT06327984

Recruiting

There is a lack of understanding of how Coronary Artery Disease (CAD) - meaning the blocking or furring up of the arteries of the heart - starts and progresses in women. In both men and women, CAD is the most common cause of heart attacks, which occur when the blood supply in the heart is interrupted (these are also known medically as 'acute coronary syndromes'). Before the menopause women appear to be protected from CAD; however, after the menopause that protection is lost. Also, those women w... Read More

There is a lack of understanding of how Coronary Artery Disease (CAD) - meaning the blocking or furring up of the arteries of the heart - starts and progresses in women. In both men and women, CAD is the most common cause of heart attacks, which occur when the blood supply in the heart is interrupted (these are also known medically as 'acute coronary syndromes'). Before the menopause women appear to be protected from CAD; however, after the menopause that protection is lost. Also, those women who do suffer a heart attack have twice the risk of further heart attacks compared to men despite having the same treatment that works well in men. Biological differences between men and women are probably playing an important role in the way CAD develops. However, due to a lack of research there is currently little understanding of how the female body works in this area. Inflammation is the body's natural response to injury or infection. Importantly it is also involved in the development of CAD. Hormones such as oestrogen and testosterone are also likely to be contributory factors. The investigators think the differences between the way these hormones and inflammation play a part in CAD in both men and women are important, but the role they play is not yet fully understood. In this study the investigators wish to measure the 'markers' of inflammation in the blood of patients attending Barts Heart Centre with chest pain. The investigators will also conduct questionnaires with these patients, to understand their hormone status and how parts of their medical history may be a contributory factor. For patients who have previously attended Barts Heart Centre will will contact them to conduct the questionnaire over the telephone only. The investigators will combine this data with the data that is routinely collected during hospital admission. In this way the investigators hope to understand whether inflammation together with hormone status plays an important role in CAD. Our hope is that through this research the investigators will address an under researched area and find new ways of treating women and men with coronary artery disease. Read Less

Gender:

ALL

Ages:

16 years and above

Trial Updated:

07/23/2025

Locations: Barts Health NHS Trust, London, Not set

Conditions: Coronary Artery Disease, Myocardial Infarction, Acute Coronary Syndrome, Atherosclerosis, Inflammation

Register for Updates

Learn More ›

A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants

NCT06547164

Recruiting

This study will be conducted in order to determine the effect of repeated oral doses of camizestrant on the pharmacokinetics (PK) of midazolam and to determine the effect of repeated oral titrated doses of carbamazepine on the PK of camizestrant in healthy post-menopausal female participants.

Gender:

FEMALE

Ages:

Between 50 years and 70 years

Trial Updated:

07/23/2025

Locations: Research Site, Harrow, Not set

Conditions: Healthy Participants

Register for Updates

Learn More ›

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

NCT05797168

Recruiting

This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors

Gender:

ALL

Ages:

Between 18 years and 130 years

Trial Updated:

07/23/2025

Locations: Research Site, Duarte, California +58 locations

Research Site, Duarte, California

Research Site, Irvine, California

Research Site, La Jolla, California

Research Site, Aurora, Colorado

Research Site, Louisville, Kentucky

Research Site, Boston, Massachusetts

Research Site, Detroit, Michigan

Research Site, Columbus, Ohio

Research Site, Portland, Oregon

Research Site, Providence, Rhode Island

Research Site, Houston, Texas

Research Site, Fairfax, Virginia

Research Site, Liverpool, Not set

Research Site, Melbourne, Not set

Research Site, Edmonton, Alberta

Research Site, London, Ontario

Research Site, Toronto, Ontario

Research Site, Montréal, Quebec

Research Site, Chengdu, Not set

Research Site, Chongqing, Not set

Research Site, Guangzhou, Not set

Research Site, Jinan, Not set

Research Site, Xi'an, Not set

Research Site, Zhengzhou, Not set

Research Site, Berlin, Not set

Research Site, Essen, Not set

Research Site, Hannover, Not set

Research Site, Leipzig, Not set

Research Site, Mannheim, Not set

Research Site, Regensburg, Not set

Research Site, Haifa, Not set

Research Site, Ramat Gan, Not set

Research Site, Hidaka-shi, Not set

Research Site, Kashiwa, Not set

Research Site, Koto-ku, Not set

Research Site, Sunto-gun, Not set

Research Site, Tokyo, Not set

Research Site, Seoul, Not set

Research Site, Barcelona, Not set

Research Site, Madrid, Not set

Research Site, Málaga, Not set

Research Site, Taichung, Not set

Research Site, Tainan City, Not set

Research Site, Taipei, Not set

Research Site, Ankara, Not set

Research Site, Istanbul, Not set

Research Site, Cambridge, Not set

Research Site, Glasgow, Scotland, Not set

Research Site, London, Not set

Research Site, Sutton, Not set

Conditions: Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer

Register for Updates

Learn More ›

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

NCT06868277

Recruiting

The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/23/2025

Locations: Research Site, Bay Pines, Florida +179 locations

Research Site, Bay Pines, Florida

Research Site, Clearwater, Florida

Research Site, Saint Petersburg, Florida

Research Site, Marietta, Georgia

Research Site, Decatur, Illinois

Research Site, Des Moines, Iowa

Research Site, Leawood, Kansas

Research Site, Lexington, Kentucky

Research Site, Frederick, Maryland

Research Site, Silver Spring, Maryland

Research Site, Towson, Maryland

Research Site, Lincoln, Nebraska

Research Site, Paramus, New Jersey

Research Site, Westbury, New York

Research Site, Canton, Ohio

Research Site, Philadelphia, Pennsylvania

Research Site, Aberdeen, Washington

Research Site, Cordoba, Not set

Research Site, Rosario, Not set

Research Site, Hobart, Not set

Research Site, Woolloongabba, Not set

Research Site, Edegem, Not set

Research Site, Liège, Not set

Research Site, Mechelen, Not set

Research Site, Roeselaere, Not set

Research Site, Blumenau, Not set

Research Site, Fortaleza, Not set

Research Site, Ijui, Not set

Research Site, Itajai, Not set

Research Site, Londrina, Not set

Research Site, Passo Fundo, Not set

Research Site, Porto Alegre, Not set

Research Site, Porto Velho, Not set

Research Site, São Paulo, Not set

Research Site, Burgas, Not set

Research Site, Panagyurishte, Not set

Research Site, Sofia, Not set

Research Site, Kelowna, British Columbia

Research Site, Cambridge, Ontario

Research Site, Toronto, Ontario

Research Site, Baoding, Not set

Research Site, Beijing, Not set

Research Site, Changchun, Not set

Research Site, Changsha, Not set

Research Site, Chongqing, Not set

Research Site, Fuzhou, Not set

Research Site, Guangzhou, Not set

Research Site, Jiamusi, Not set

Research Site, Jinan, Not set

Research Site, Lanzhou, Not set

Research Site, Linyi, Not set

Research Site, Nanchang, Not set

Research Site, Nanjing, Not set

Research Site, Ningbo, Not set

Research Site, Shanghai, Not set

Research Site, Shenyang, Not set

Research Site, Suzhou, Not set

Research Site, Wuhan, Not set

Research Site, Xuzhou, Not set

Research Site, Yantai, Not set

Research Site, Valledupar, Not set

Research Site, Angers, Not set

Research Site, Avignon, Not set

Research Site, Caen, Not set

Research Site, Dijon, Not set

Research Site, La Tronche, Not set

Research Site, Limoges, Not set

Research Site, Nantes CEDEX 1, Not set

Research Site, Paris, Not set

Research Site, Pau Cedex, Not set

Research Site, Toulouse, Not set

Research Site, Tbilisi, Not set

Research Site, Amberg, Not set

Research Site, Bad Saarow, Not set

Research Site, Berlin, Not set

Research Site, Bonn, Not set

Research Site, Essen, Not set

Research Site, Frankfurt am Main, Not set

Research Site, Heilbronn, Not set

Research Site, Immenhausen, Not set

Research Site, Koblenz, Not set

Research Site, Leipzig, Not set

Research Site, München, Not set

Research Site, Oldenburg, Not set

Research Site, Rotenburg, Not set

Research Site, Schweinfurt, Not set

Research Site, Velbert, Not set

Research Site, Würselen, Not set

Research Site, Würzburg, Not set

Research Site, Athens, Not set

Research Site, Peiraias, Not set

Research Site, Thessaloniki, Not set

Research Site, Afula, Not set

Research Site, Beer-Sheva, Not set

Research Site, Hadera, Not set

Research Site, Haifa, Not set

Research Site, Jerusalem, Not set

Research Site, Ramat Gan, Not set

Research Site, Tel Aviv, Not set

Research Site, Tel-Aviv, Not set

Research Site, Candiolo, Not set

Research Site, Lucca, Not set

Research Site, Napoli, Not set

Research Site, Peschiera Del Garda, Not set

Research Site, Pisa, Not set

Research Site, Udine, Not set

Research Site, Verona, Not set

Research Site, Akashi, Not set

Research Site, Bunkyo-ku, Not set

Research Site, Fukuoka-shi, Not set

Research Site, Fukuoka-Shi, Not set

Research Site, Hamamatsu-shi, Not set

Research Site, Iwakuni-shi, Not set

Research Site, Izumi-shi, Not set

Research Site, Kashihara-shi, Not set

Research Site, Kobe, Not set

Research Site, Koto-ku, Not set

Research Site, Kurume-shi, Not set

Research Site, Kyoto-shi, Not set

Research Site, Matsuyama-shi, Not set

Research Site, Nankoku-shi, Not set

Research Site, Niigata-shi, Not set

Research Site, Osaka-shi, Not set

Research Site, Osakasayama, Not set

Research Site, Sakai-shi, Not set

Research Site, Sendai-shi, Not set

Research Site, Shinagawa-ku, Not set

Research Site, Toyoake-shi, Not set

Research Site, Toyonaka-shi, Not set

Research Site, Jinju-si, Not set

Research Site, Seoul, Not set

Research Site, Kuala Lumpur, Not set

Research Site, Perai, Not set

Research Site, Selangor, Not set

Research Site, Alcabideche, Not set

Research Site, Lisboa, Not set

Research Site, Lisbon, Not set

Research Site, Porto, Not set

Research Site, Bucuresti, Not set

Research Site, Craiova, Not set

Research Site, Iasi, Not set

Research Site, Pitesti, Not set

Research Site, Badalona, Not set

Research Site, Castellón, Not set

Research Site, Granada, Not set

Research Site, Madrid, Not set

Research Site, Málaga, Not set

Research Site, Oviedo, Not set

Research Site, Valencia, Not set

Research Site, Bakirkoy, Not set

Research Site, Izmit, Not set

Research Site, Yüreğir, Not set

Research Site, Çankaya, Not set

Research Site, Blackpool, Not set

Research Site, Hull, Not set

Research Site, Stevenage, Not set

Conditions: Carcinoma, Non-Small Cell Lung

Register for Updates

Learn More ›

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

NCT05503797

Recruiting

The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare BRAF V600-mutated solid tumors, melanoma, thyroid, or recurrent primary CNS tumors.

Gender:

ALL

Ages:

10 years and above

Trial Updated:

07/23/2025

Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California +59 locations

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

University of California Los Angeles Rheumatology, Westwood, California

University of Miami Hospital and Clinics, Miami, Florida

The John Hopkins Hospital, Baltimore, Maryland

Maryland Oncology Hematology- Columbia, Rockville, Maryland

Tufts Medical Center, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

St. Luke's Hospital, Duluth, Minnesota

Mosaic Life Care at Saint Joseph - Medical Center, Saint Joseph, Missouri

Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha, Nebraska

Overlook Medical Center, Summit, New Jersey

Columbia University Irving Medical Center, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Nationwide Children's Hospital, Columbus, Ohio

Taylor Cancer Research Center, Maumee, Ohio

Toledo Clinic Cancer Center, Toledo, Ohio

Thomas Jefferson University, Philadelphia, Pennsylvania

Lifespan Cancer Institute - Rhode Island Hospital, Providence, Rhode Island

Baylor Scott & White Research Institute, Dallas, Texas

Baylor Scott & White Medical Center, Temple, Texas

University of Washington School of Medicine, Seattle, Washington

West Virginia University Health Sciences Campus, Morgantown, West Virginia

Newcastle Private Hospital, New Lambton Heights, New South Wales

Orange Health Service, Orange, New South Wales

Sydney Children's Hospital Network - Randwick, Randwick, New South Wales

The Alfred, Melbourne, Victoria

Sunny brook Health Sciences Centre- Bayview Campus, Toronto, Ontario

Centre Hospitalier Universitaire Sainte-Justine, Montréal, Quebec

Institut Bergonie, Bordeaux Cedex, Aquitaine

Hôpital Nord de Marseille, Marseille, Bouches-du-Rhône

Hôpital Morvan, Brest, Finistère

Hôpital Universitaire Pitié Salpêtrière, Paris, Ile-de-France

Institut de Cancerologie de l'Ouest- Angers, Angers, Pays De La Loire

Gustave Roussy, Villejuif, Val-de-Marne

Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, Not set

Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg

Krankenhaus Nordwest, Frankfurt, Hessen

Charité - Universitätsmedizin Berlin, Berlin, Not set

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola, Forli-Cesena

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Naples

Istituto Europeo di Oncologia, Milano, Not set

Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele, Milan, Not set

Catholic University of Korea Saint Vincent's Hospital, Suwon-si, Gyeonggi-do

Seoul National University Hospital, Suwon, Gyeonggido

Dong-A University Hospital, Busan, Gyeongsangnam-do

Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do

Seoul National University Hospital, Seoul, Seoul Teugbyeoisi

Severance Hospital, Seoul, Seoul Teugbyeolsi

Haukeland Univeritetssjukehus, Bergen, Hordaland

Oslo Universitetssykehus-Radiumhospitalet, Oslo, Not set

Hospital Clinico Universitarlo de Santiago, Santiago De Compostela, A Coruña

Hospital Clinico Universitarlo de Valencia, València, Valencia

Hospital Universitari Vall d'Hebron, Barcelona, Not set

Hospital Infantil Universitario Niño Jesús, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario Virgen del Rocío, Sevilla, Not set

Skånes Universitetssjukhus, Lund, Skåne Län

Karolinska Universitetssjukhuset, Solna, Stockholms Län

The Christie NHS Foundation Trust, Manchester, England

Sarah Cannon Research Institute, London, Not set

Conditions: Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors, Melanoma BRAF V600E/K Mutated, Thyroid Cancer

Register for Updates

Learn More ›

DERMATOMICS: Identifying Regulators of Skin Homeostasis

NCT06894654

Recruiting

Diseases of the skin associated with chronic immune driven conditions, including scleroderma, lupus, dermatomyositis, psoriasis, and atopic dermatitis, significantly impact skin integrity, function, and overall quality of life. These conditions can lead to severe disfigurement, discomfort, and systemic complications, necessitating long-term medical intervention. The prevalence of these skin disorders is rising globally, driven by genetic, environmental, and immunological factors. Unravelling the... Read More

Diseases of the skin associated with chronic immune driven conditions, including scleroderma, lupus, dermatomyositis, psoriasis, and atopic dermatitis, significantly impact skin integrity, function, and overall quality of life. These conditions can lead to severe disfigurement, discomfort, and systemic complications, necessitating long-term medical intervention. The prevalence of these skin disorders is rising globally, driven by genetic, environmental, and immunological factors. Unravelling the mechanisms leading to skin manifestations may shed further insights in the overall mechanisms of disease. The DERMATOMICS study will focus on understanding systemic sclerosis (SSc) biology. Systemic Sclerosis (SSc) is a highly heterogeneous rare autoimmune fibrotic condition affecting the skin and internal organs. SSc is classified as a Connective Tissue Disease (CTD), a family of conditions including Systemic Lupus Erythematosus, Sjogren Syndrome and Inflammatory Myositis, all characterised by an autoimmune process affecting the connective tissue of most organs, communed by the presence of anti-nuclear antibodies (ANA). In SSc, patients are affected by a combination of tissue and vascular fibrosis, on the background of a chronic inflammatory process, leading to the highest per patient morbidity and mortality across CTDs. The main driver of mortality to date is interstitial lung disease (ILD), which is the consequence of the fibrotic involvement of the lungs, leading to a progressive loss of functional lung volumes, and ultimately, derangement of lung circulation, hypoxia, increased risk of hospitalisation for lower respiratory infections and death. Current treatments for CTDs include general immunosuppressive treatments, not necessarily targeted to the specific mechanisms underlying their presentation, focusing on reducing inflammation and managing symptoms rather than addressing the underlying causes. Many of these therapies have limited effectiveness or are burdened with significant side effects. Therefore, there is a critical need to develop a comprehensive understanding of the cellular and molecular mechanisms underlying these disorders to identify novel therapeutic targets. Several factors contribute to the risk and severity of SSc, including genetic predisposition, environmental triggers, immune system dysregulation, and lifestyle factors such as diet and smoking. The interactions between these factors are complex and not fully understood. By recruiting participants with SSc, we aim to obtain skin punch biopsies for detailed molecular and genetic analysis. To increase the informative value of our study we plan to implement an extreme phenotype approach and include participants with opposite degrees of severity. Our study aims to elucidate the relationships between the molecular biology of skin cells, skin structure, genetic factors ("DNA"), and environmental influences. The goal is to identify and validate novel therapeutic targets that can lead to more effective and personalised treatment options for SSc, and more broadly for CTDs and CTD-associated skin and lung disease. Modern single-cell technologies will be employed to dissect the cellular diversity within the skin. These advanced techniques have revolutionised our understanding of many tissues, but skin tissues remain underexplored, especially in the context of chronic skin diseases. Protocols for skin punch biopsy and single-cell profiling are well-established, allowing us to systematically analyse how genetic variations influence skin structure and function. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/23/2025

Locations: Chapel Allerton Hospital, Leeds, Not set +1 locations

Conditions: Systemic Sclerosis (SSc)

Register for Updates

Learn More ›

Pancreatic Cancer Early Detection Consortium

NCT04970056

Recruiting

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.

Gender:

ALL

Ages:

Between 18 years and 90 years

Trial Updated:

07/23/2025

Locations: Mayo Clinic Arizona, Phoenix, Arizona +59 locations

Mayo Clinic Arizona, Phoenix, Arizona

Honor Health Research Institute, Scottsdale, Arizona

Providence Health and Services, Burbank, California

City of Hope, Duarte, California

UC San Diego Moores Cancer Center, La Jolla, California

Cedars-Sinai Medical Center, Los Angeles, California

UCLA Health, Los Angeles, California

Hoag, Newport Beach, California

UC Irvine Health, Orange, California

UC Davis, Sacramento, California

University of California, San Francisco (UCSF), San Francisco, California

Yale University, New Haven, Connecticut

Mayo Clinic Jacksonville, Jacksonville, Florida

University of Miami, Miami, Florida

Moffitt Cancer Center, Tampa, Florida

Emory University Hospital, Atlanta, Georgia

Illinois CancerCare, Bloomington, Illinois

University of Chicago Medicine, Chicago, Illinois

NorthShore University HealthSystem, Evanston, Illinois

University of Kansas Medical Center, Kansas City, Kansas

Massachusetts General Hospital, Boston, Massachusetts

Umass Memorial Medical Center, Worcester, Massachusetts

University of Michigan, Ann Arbor, Michigan

Beaumont/Corewell Health, Royal Oak, Michigan

University of Nebraska Medical Center, Omaha, Nebraska

Hackensack Meridian Health, Hackensack, New Jersey

Memorial Sloan Kettering Cancer Center, New York, New York

Icahn School of Medicine At Mount Sinai, New York, New York

Columbia University Irving Medical Center, New York, New York

University of Rochester Medical Center, Rochester, New York

White Plains Hospital, White Plains, New York

The Ohio State University, Columbus, Ohio

Oregon Health & Science University, Portland, Oregon

University of Pennsylvania, Philadelphia, Pennsylvania

Fox Chase Cancer Center, Philadelphia, Pennsylvania

University of Pittsburgh Medical Center (Upmc), Pittsburgh, Pennsylvania

University of Tennessee Graduate School of Medicine, Knoxville, Tennessee

The University of Texas Southwestern Medical Center, Dallas, Texas

MD Anderson Center, Houston, Texas

Intermountain Health, Saint George, Utah

Huntsman Cancer Institute, Salt Lake City, Utah

University of Virginia, Charlottesville, Virginia

Inova Schar Cancer Institute, Fairfax, Virginia

VCU Massey Comprehensive Cancer Center, Richmond, Virginia

University of Washington, Seattle, Washington

Epworth HealthCare, Richmond, Victoria

British Columbia Cancer Agency, Vancouver, British Columbia

University Health Network, Toronto, Ontario

McGill University Health Centre, Montreal, Quebec

Semmelweis University, Institute of Pancreatic Diseases, Budapest, Not set

Landspitali University Hospital, Reykjavík, Not set

Sheba Medical Center, Ramat Gan, Not set

Azienda Ospedaliera Universitaria Integrata Verona, Verona, Not set

National Cancer Centre Singapore, Singapore, Not set

Hospital Clínic de Barcelona, Barcelona, Not set

Hospital Universitari Arnau De Vilanova, Lleida, Not set

Ramón y Cajal University Hospital, Madrid, Not set

National Cheng Kung University Hospital (NCKUH), Tainan, Taiwan T.O.C.

National Taiwan University Hospital, Taipei, Not set

University of Liverpool, Liverpool, Not set

Conditions: Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition

Register for Updates

Learn More ›

Combined Blood Pressure Medication and Activity Scheduling for Low Mood

NCT07017023

Recruiting

This study explores the effects of 7-day losartan (50mg) versus placebo with brief behavioural activation on emotional processing in young volunteers low in positive mood

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

07/23/2025

Locations: Warneford Hospital, University of Oxford, Oxford, Oxfordshire

Conditions: Emotional Processing, Mood

Register for Updates

Learn More ›

All Clinical Trials in United Kingdom

Match to Clinical Trials